This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Griffiths, G. L. Articles by Goldenberg, D. M. Search for Related Content PubMed PubMed Citation Articles by Griffiths, G. L. Articles by Goldenberg, D. M.

Cure of SCID Mice Bearing Human B-Lymphoma Xenografts by an Anti-CD74 Antibody-Anthracycline Drug Conjugate

¹ Immunomedics, Inc., Morris Plains, and
² Garden State Cancer Center, Belleville, New Jersey

Purpose: The purpose of this research was to test the therapeutic efficacy of an anthracycline-antibody conjugate for the treatment of human B-cell lymphoma in a preclinical animal model.

Experimental Design: Doxorubicin (dox) conjugates of the murine and humanized versions of the anti B-cell antibody LL1, targeting CD74, were prepared, along with a nonspecific control dox-antibody conjugate, targeting carcinoembryonic antigen. Antibody conjugates carried approximately 8–10 drug molecules attached site-specifically at thiols of reduced interchain disulfide bonds. Conjugates were tested, initially in vitro, and then for therapeutic efficacy in a systemic model, using a lethal i.v. dose of Raji cells in SCID mice.

Results: Dox-LL1 conjugates were shown to be stable and 3-fold more effective in vitro against the human B-cell Burkitt’s lymphoma line, Raji, compared with the nonspecific control conjugate that did not target CD74 or B cells. When SCID mice were given an i.v. dose of 2.5 million Raji cells, they would die of disseminated disease within 15–25 days postinjection. A single dose of dox-LL1 conjugate, 117–350 µg, given 5 days to 14 (advanced disease) days after injection of the Raji cells resulted in cure of most animals out to 180 days after injection of the cells, whereas animals in treatment control groups were not cured. The dose of dox-LL1 found useful in this work corresponds with a significantly lower drug dose than reported previously with other drug-antibody conjugates

Conclusion: CD74 appears to be a uniquely useful target antigen for delivery of drugs, effecting cures of animals with single, low doses of conjugate.

This article has been cited by other articles:

				T. Schluep, P. Gunawan, L. Ma, G. S. Jensen, J. Duringer, S. Hinton, W. Richter, and J. Hwang Polymeric Tubulysin-Peptide Nanoparticles with Potent Antitumor Activity Clin. Cancer Res., January 1, 2009; 15(1): 181 - 189. [Abstract] [Full Text] [PDF]

				R. Stein, M. J. Mattes, T. M. Cardillo, H. J. Hansen, C.-H. Chang, J. Burton, S. Govindan, and D. M. Goldenberg CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms Clin. Cancer Res., September 15, 2007; 13(18): 5556s - 5563s. [Abstract] [Full Text] [PDF]

				R. M. Sharkey and D. M. Goldenberg Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates CA Cancer J Clin, July 1, 2006; 56(4): 226 - 243. [Abstract] [Full Text] [PDF]

				R. Greupink, H. I. Bakker, W. Bouma, C. Reker-Smit, D. K. F. Meijer, L. Beljaars, and K. Poelstra The Antiproliferative Drug Doxorubicin Inhibits Liver Fibrosis in Bile Duct-Ligated Rats and Can Be Selectively Delivered to Hepatic Stellate Cells in Vivo J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 514 - 521. [Abstract] [Full Text] [PDF]

				N. Koide, T. Yamada, R. Shibata, T. Mori, M. Fukuma, K. Yamazaki, K. Aiura, M. Shimazu, S. Hirohashi, Y. Nimura, et al. Establishment of Perineural Invasion Models and Analysis of Gene Expression Revealed an Invariant Chain (CD74) as a Possible Molecule Involved in Perineural Invasion in Pancreatic Cancer Clin. Cancer Res., April 15, 2006; 12(8): 2419 - 2426. [Abstract] [Full Text] [PDF]

				C.-H. Chang, P. Sapra, S. S. Vanama, H. J. Hansen, I. D. Horak, and D. M. Goldenberg Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin Blood, December 15, 2005; 106(13): 4308 - 4314. [Abstract] [Full Text] [PDF]

				P. Sapra, R. Stein, J. Pickett, Z. Qu, S. V. Govindan, T. M. Cardillo, H. J. Hansen, I. D. Horak, G. L. Griffiths, and D. M. Goldenberg Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in Monkeys Clin. Cancer Res., July 15, 2005; 11(14): 5257 - 5264. [Abstract] [Full Text] [PDF]

				R. Stein, Z. Qu, T. M. Cardillo, S. Chen, A. Rosario, I. D. Horak, H. J. Hansen, and D. M. Goldenberg Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies Blood, December 1, 2004; 104(12): 3705 - 3711. [Abstract] [Full Text] [PDF]

				J. D. Burton, S. Ely, P. K. Reddy, R. Stein, D. V. Gold, T. M. Cardillo, and D. M. Goldenberg CD74 Is Expressed by Multiple Myeloma and Is a Promising Target for Therapy Clin. Cancer Res., October 1, 2004; 10(19): 6606 - 6611. [Abstract] [Full Text] [PDF]